EN DE
Watch Rion Co., Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Rion Co., Ltd (RIOXF) fair value: what the stock is really worth

As of Sep 30, 2026: fair value (intrinsic value) of Rion Co., Ltd stock $31.66, price $14.63, upside +116.4%, quality 70 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Based in Japan

RC Rion Co., Ltd logo Broad data Nov 8, 2026

Rion Co., Ltd

RIOXF · US
Meets all rules

The stock costs 54% less than our calculation considers fair.

Fair value $31.66 · Strongly undervalued
Quality 70/100
Healthy Growth (revenue 5y +6.8 %/yr in JPY)
Solidly profitable · 12.0% net margin (TTM)
Generates free cash flow
3.7% dividend yield · Well covered
Ranks above peers (12/13)
Broad data
Even on cautious assumptions the value is 48% above the price ($21.63).
Moderate moat 58/100
⚠ Thinly traded
Watch Rion Co., Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$18.04 $13.36 Fair Value $31.66 Jan 2024 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

33‑month range $13.36 – $18.04 · fair‑value band $21.63 – $42.90 · the $14.63 price screens below the $31.66 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.

Follow Rion Co. in your weekly email

Every Wednesday you see whether Rion Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Rion Co., Ltd. develops, manufactures, sells, and services particle counters, medical equipment, and environmental equipment in Japan.

Show moreShow less

The company's audiological equipment includes hearing instruments, such as analog and digital BTE, trimmer digital BTE, in-the-ear ready and custom-made, and analog body aid instruments, as well as wireless and waterproof hearing instruments; and medical equipment comprising audiometers and OAE screeners.

Its sound and vibration measuring instruments include sound level meters, vibration meters, seismometers, frequency analyzers, microphones and recorders, and other products. The company's particle counters comprise air and liquid-borne particle counters, and viable particle counters.

Its products are primarily used in the applications of environment-related administration, electronics, semiconductors, pharmaceutical, and food manufacturing industries. The company was formerly known as Kobayashi-Riken Seisakusho Ltd. and changed its name to Rion Co., Ltd. in 1960.

Rion Co., Ltd. was incorporated in 1944 and is headquartered in Kokubunji, Japan.

Stock analysis

Rion Co., Ltd (RIOXF) currently trades at $14.63, while our model-based Fair Value estimate is $31.66, implying the stock looks roughly 54% undervalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of $39.41 per share, and 20 of the 26 models we run sit above the $14.63 price.

Bear case: the Dividend Discount group reads lowest at $5.95, and 6 of the 26 models stay below the price. Data coverage for this calculation is high.

Scenario range: $21.63 (bear) to $42.90 (bull), the price of $14.63 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 70/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Rion Co., Ltd reported revenue of ¥28.5B in FY2026 versus ¥22.6B in FY2022, a compound +5.9%/yr. Reported net income was ¥3.3B in FY2026, compounding +10.7%/yr from FY2022.

Key figures

Market cap $180M Micro · P/E ratio 8.8 · P/S ratio 1.03 · EPS (TTM) $1.66 · Dividend yield 3.7% · Net margin 11.7% · Return on equity 10.3% · Return on assets (EBIT) 9.7% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 58 out of 100 (medium confidence).

What moves the price

The share trades at its 52-week high and 6% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at 116%, RIOXF screens cheaper than that median.

Fair Value models

Bear $21.63 Fair Value $31.66 Bull $42.90
Price $14.63 · Upside +116.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then ($0.6860 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $18.75 $25.27 $33.70 79
Growth DCF $18.83 $24.50 $31.38 77
Residual Income $13.45 $14.60 $17.05 76
All 26 models by family
DCF Models
FCF DCF $18.75 $25.27 $33.70 79
Owner Earnings $18.15 $24.43 $32.54 75
5Y Revenue Exit $20.83 $31.26 $44.49 70
5Y EBITDA Exit $25.60 $40.13 $57.00 72
5Y P/E Exit $24.19 $37.50 $51.38 68
10Y Revenue Exit $19.25 $27.84 $39.21 64
10Y EBITDA Exit $22.46 $33.33 $47.69 66
10Y P/E Exit $21.65 $31.70 $43.88 62
Earnings-Based
Graham-Dodd $11.66 $35.58 $47.22 65
Lynch FV $7.63 $10.91 $14.18 61
PEG = 1.0 $7.63 $10.91 $14.18 57
EPV $16.65 $18.41 $19.87 68
Dividend Discount
Gordon GGM $3.63 $6.36 $8.55 68
DDM Multi-Stage $3.63 $5.53 $6.81 67
Multiples
P/E Multiple $28.29 $37.72 $47.15 63
P/S Multiple $21.86 $29.15 $36.44 58
P/B Multiple $50.50 $67.34 $84.17 55
EV/EBIT $31.59 $41.09 $50.59 63
EV/EBITDA $34.11 $44.45 $54.80 64
EV/Revenue $23.43 $32.14 $40.86 51
Asset-Based
NCAV (Graham) $5.07 $7.68 $9.60 52
Growth DCF
Growth DCF $18.83 $24.50 $31.38 77
Rev-Margin DCF $20.83 $31.29 $43.23 70
Economic Profit
Residual Income $13.45 $14.60 $17.05 76
ROIC Compounder $16.75 $19.31 $22.18 70
Growth Earnings
Growth-Adj P/E $23.13 $33.04 $42.95 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 70/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 54
How much profit the company makes from its sales and capital
Quality Growth 50
Are margins and returns getting better?
Cashflow 60
Do the profits arrive as real cash?
Financial strength 84
Debt, balance sheet and risk of trouble
Investment 82
Does it invest with discipline instead of growing at any price?
Low Volatility 95
How calm the share price moves, does not count
Price momentum 43
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 70
Distance to the 52-week high, does not count
New shares 81
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 78/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+2.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.8%
Start year 2021 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.8%
What shareholders gained per year (last 5 years), in JPY ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in JPY: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+17.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+13.4%
Dividend (yield on the price)3.7%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.11% → 15%

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−7.2%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (figures in JPY, Japan: IMF forecast 2.1% a year to 2030, 1.3% from 2016 to 2025) that is about −9.1% a year for the price.

Watch RIOXF, get fair value alerts →

Compare Rion Co., Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 320 stocks

Beats the industry median on 12/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 70 · Top 25%
Fair Value upside +116.4% · Top 25%
Profitability
Return on equity (12 months) 10.3% · Above median
Return on assets 8.6% · Top 25%
Net margin (12 months) 12.0% · Above median
Operating margin (12 months) 14.4% · Above median
Growth and dividend
Revenue growth (quarter YoY) 3.9% · Below median
Dividend yield (12 months) 3.7% · Top 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/E (12 months) 8.8× · Cheapest 25%
P/B 0.91× · Cheapest 25%
P/S (12 months) 0.99× · Cheapest 25%
Price / free cash flow (fiscal year) 8.4× · Cheapest 25%
EV/EBITDA 3.8× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 6
FUTURE (revenue growth)20 · sector 35
PAST (return on equity)41 · sector 17
HEALTH (low debt)0 · sector 98
DIVIDEND (yield)73 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Rion Co., Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Rion Co., Ltd Fair Value". https://www.fairvalue-calculator.com/stock/RIOXF

Frequently asked questions

Is Rion Co., Ltd (RIOXF) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of $31.66 versus the last price from Sep 30, 2026 of $14.63, about +116% upside (undervalued).
What is the fair value of RIOXF?
Our model-based fair value for Rion Co., Ltd is $31.66 (as of Nov 8, 2026), built from audited fundamentals. Last price (from Sep 30, 2026): $14.63.
What is the quality score of RIOXF?
Rion Co., Ltd has a Quality Score of 70/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Rion Co., Ltd (RIOXF)?
Our model-based price target is the fair value of $31.66 (as of Nov 8, 2026) from 26 valuation models. Cautious scenario $21.63, optimistic scenario $42.90. It is a calculation from audited fundamentals, not an analyst target.
What is the Rion Co., Ltd stock forecast for 2026?
Our models put fair value at $31.66, about +116% upside versus the last price from Sep 30, 2026 of $14.63 (undervalued). Cautious scenario $21.63, optimistic scenario $42.90. The calculation is refreshed regularly with new filings.
What is the revenue of Rion Co., Ltd (RIOXF)?
Rion Co., Ltd reported trailing-twelve-month revenue of about ¥28.8B (latest available figure, as of Nov 8, 2026).
Does Rion Co., Ltd pay a dividend?
Rion Co., Ltd currently shows a dividend yield of 3.67% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Rion Co., Ltd (RIOXF) and when is the ex-dividend date?
Rion Co., Ltd pays a dividend of $0.537 per share a year, a dividend yield of 3.7%. The next ex-dividend date is Mar 30, 2027. The payout ratio is 31.3% of earnings. Free cash flow covers the dividend 3.26 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Rion Co., Ltd (RIOXF)?
For today's price to be fair in a discounted-cash-flow model, Rion Co., Ltd would have to grow free cash flow by -7.2 % per year for five years (discount rate 11.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +6.9 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of RIOXF use?
Our models discount Rion Co., Ltd at 11.5 %: a base by market capitalisation (micro), damped by beta 0.62, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Rion Co., Ltd that is -7.2 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.5 %) and the same formula as our fair value.
How much growth has Rion Co., Ltd (RIOXF) delivered so far?
Over the past 5 years revenue at Rion Co., Ltd grew +6.9 % a year. The price currently implies free-cash-flow growth of -7.2 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Rion Co., Ltd (RIOXF) growing?
The median revenue growth in the sector is +1.7 % a year. That is the yardstick for the growth priced into Rion Co., Ltd (-7.2 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Rion Co., Ltd (RIOXF)?
The free-cash-flow yield on the price is 11.96 %: that much free cash flow Rion Co., Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Rion Co., Ltd (RIOXF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Rion Co., Ltd it is $31.66 per share (as of Nov 8, 2026), against a price of $14.63. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Rion Co., Ltd stock overvalued or undervalued in 2026?
As of Nov 8, 2026, RIOXF trades below its calculated fair value: price $14.63, fair value $31.66, a gap of about +116% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RIOXF?
No. The price is what the market pays today ($14.63); the fair value is what the company's own numbers justify ($31.66). For Rion Co., Ltd the two are $17.03 per share apart. That gap is exactly why we show both numbers side by side.
How much is Rion Co., Ltd worth?
The market values Rion Co., Ltd at about $180M (market capitalisation, as of Nov 8, 2026). Per share that is $14.63; our models calculate a fair value of $31.66 per share.
What do the bullish and bearish scenarios say about RIOXF?
Our models span a range for Rion Co., Ltd: cautious scenario $21.63, base $31.66, optimistic $42.90 per share (as of Nov 8, 2026, price $14.63). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of RIOXF?
Rion Co., Ltd trades at a price-to-earnings ratio of 8.8 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $31.66 is built from several models across several years. Other multiples: P/B 0.9, P/S 1.0, EV/EBITDA 3.8.
How solid is the balance sheet of Rion Co., Ltd (RIOXF)?
Balance-sheet figures for Rion Co., Ltd (as of Nov 8, 2026): return on equity 10.3%. They feed the Quality Score of 70/100, which measures business quality independently of the share price.
How far is RIOXF from its 52-week high?
Rion Co., Ltd trades at $14.63, at its 52-week high of $14.63 and 6% above the low of $13.80 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $31.66 is for.
Which stocks are comparable to Rion Co., Ltd?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Rion Co., Ltd stock attractive at the current price?
The data as of Nov 8, 2026: price $14.63, calculated fair value $31.66 (+116%), Quality Score 70/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RIOXF calculated?
We run Rion Co., Ltd through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $31.66 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Rion Co., Ltd currently trades 54% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Rion Co., Ltd (RIOXF)?
The latest price we hold is from Sep 30, 2026 and stands at $14.63. Our model-based fair value is $31.66, about +116% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Rion Co., Ltd right now?
The price is below even our cautious bear case ($21.63). The market is more pessimistic than our downside scenario. Solid quality (70/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range ($21.63 to $42.90) leaves room in how you read the outcome.

Key figures of Rion Co., Ltd

How large is the market capitalisation of Rion Co., Ltd (RIOXF)?
The market capitalisation of Rion Co., Ltd is $180M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Rion Co., Ltd (RIOXF)?
The price-to-sales ratio of Rion Co., Ltd is 1.03 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Rion Co., Ltd (RIOXF)?
Earnings per share at Rion Co., Ltd are $1.66 (price ÷ EPS = P/E 8.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Rion Co., Ltd (RIOXF)?
The dividend yield of Rion Co., Ltd is 3.7% (payout 32.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Rion Co., Ltd (RIOXF)?
The net margin of Rion Co., Ltd is 11.7% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Rion Co., Ltd (RIOXF)?
The return on equity (ROE) of Rion Co., Ltd is 10.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Rion Co., Ltd (RIOXF)?
On an EBIT basis the return on assets of Rion Co., Ltd is 9.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Rion Co., Ltd (RIOXF)?
The operating margin of Rion Co., Ltd is 14.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Rion Co., Ltd (RIOXF)?
Revenue at Rion Co., Ltd is growing +3.9% versus a year earlier (3y avg +6.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Rion Co., Ltd (RIOXF)?
Earnings per share at Rion Co., Ltd are growing +15.3% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed

Watch Rion Co., Ltd in the live analysis

One click puts Rion Co., Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.